Company will form broad-scale strategic partnerships with industry leaders in claims, EMR, formulary and provider-institutional data.
EVERSANA has announced partnerships with data and infrastructure companies, including Symphony Health and Compile, to create the industry’s first single, streamlined claims, formulary and physician dataset. The comprehensive, real-time view of the full healthcare system will drive EVERSANA’s end-to-end commercialization services to expedite and optimize targeting, access, adherence and valued outcomes, according to a company press release.
EVERSANA and Symphony Health, a provider of data, cloud-based analytics and consulting solutions to life science companies and healthcare organizations, finalized a multi-year relationship to provide access to real-time claims and electronic medical records data for more than 300 million patients. The data will be used to activate data-driven patient engagement and hub services to advance access and adherence at each stage of the product life cycle.
In addition to claims and EMR data, a partnership with Compile will further integrate physician data to drive market access and HCP engagement. By combining public, government and deep-web data with privately licensed medical and pharmacy claims data, Compile generates the ultimate system of record on every practitioner, facility, health system and event that takes place in the U.S. healthcare market. EVERSANA expects to announce a third partnership to integrate formulary data in the coming month.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.